目的 探討抗癆丸聯(lián)合莫西沙星治療肺結(jié)核的臨床療效。方法 選取2015年3月-2016年3月在鄭州市第六人民醫(yī)院進(jìn)行治療的肺結(jié)核患者96例，根據(jù)治療方案的差別分為對(duì)照組（48例）和治療組（48例）。對(duì)照組口服鹽酸莫西沙星片，1片/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服抗癆丸，1丸/次，3次/d。兩組患者均連續(xù)治療6個(gè)月。比較兩組患者治療前后臨床療效、痰菌轉(zhuǎn)陰率和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.25%和97.92%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組痰菌轉(zhuǎn)陰率為81.25%，顯著低于治療組的97.92%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清C-反應(yīng)蛋白（CRP）、白細(xì)胞介素-10（IL-10）、腫瘤壞死因子-α（TNF-α）及降鈣素原（PCT）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)降低水平優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 抗癆丸聯(lián)合莫西沙星治療肺結(jié)核效果顯著，可明顯改善機(jī)體炎性因子水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Kanglao Pills combined with moxifloxacin in treatment of pulmonary tuberculosis. Methods Patients (96 cases) with pulmonary tuberculosis in the Sixth People's Hospital of Zhengzhou from March 2015 to March 2016 were divided into control (48 cases) and treatment (48 cases) groups based on different treatments. Patients in the control group were po administered with Moxifloxacin Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Kanglao Pills on the basis of the control group, 1 pill/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy, sputum negative rate, and serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 97.92%, respectively, and there was difference between two groups (P<0.05). After treatment, the sputum negative rate in the control was 81.25%, which was significantly lower than 97.92% in the treatment group, with significant difference between two groups (P<0.05). After treatment, CRP, IL-10, NF-α, and PCT in two groups was significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kanglao Pills combined with moxifloxacin has a significant effect in treatment of pulmonary tuberculosis, can significantly improve the inflammatory factors level, which has a certain clinical application value.